EGFR and non-small cell lung carcinoma: Patients, including those with ALK/EGFR alterations, with resected stage IB–IIIA NSCLC were randomised to receive 1 year of atezolizumab or best supportive care after adjuvant platinum-doublet chemotherapy.43 There was a disease-free survival (DFS) advantage in the intention-to-treat (ITT) population (NE [non-estimable] vs 37.2 months, HR 0.81, 95% CI: 0.67–0.99).